Activity Description

HealthHIV HIV Treatment Innovation™ Certificate Program

A Multi-Module Program for Advanced HIV Care and Treatment Providers: From Managing Comorbidities to Implementing Long-Acting Injectables


As there are rapid advancements in innovative HIV treatment, provider education must be timely and relevant to support providers to manage the complexity of patient care — from long-acting agents and injectables to new strategies for managing comorbidities and treatment resistance. Start your HIV innovation journey by enrolling in the free HealthHIV HIV Treatment Innovation™ Certificate Program that features leading experts in the field discussing the latest strategies in HIV treatment and management.


By participating in this free, one-of-a-kind program, experienced providers will:

  • Develop skills to optimize HIV care

  • Receive a certificate in HIV treatment innovation

  • Earn up to 5.5 credit hours (CME, MOC, AAPA, NCPD, CPE)

  • Stay connected to the dynamic HIV treatment landscape so that your patients can benefit from new innovations!

Providers will receive the latest updates in HIV treatment innovations while establishing a solid foundational understanding of key areas such as comorbidities and the unique needs of older adults, all reinforced through guided patient-case scenarios which feature treatment individualization strategies for enhanced clinical applicability.

Target Audience
This activity is intended for experienced HIV care providers (HIV and ID specialists), as well as primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, and other professionals involved in the care of PWH. 


  • Media: Enduring Material
  • Credit Start Date: September 30, 2025
  • Credit Expiration Date: September 30, 2026
  • Time to Complete Modules 1-5: 60 minutes Per Module
  • Time to Complete Module 6: 30 minutes 
Educational Objectives

After completing this activity, the participant should be better able to:

  • Deliver comprehensive and individualized HIV care, including ART treatment and management of antiviral resistance and common coinfections and comorbidities.
  • Recognize the benefits and flexibility of available regimens for vulnerable patients with HIV, including older adults and treatment-experienced patients.
  • Apply individualized therapy for patients with HIV that is based on new and emerging strategies and addresses the diverse needs and preferences of individual patients (e.g., adolescents, pregnant persons, unstably housed individuals, and those with substance use disorders) to promote health equity.
  • Describe new and investigational ART regimens and how they can be utilized to optimize HIV treatment.
Program Agenda

         Module 1: Innovations in Antiretroviral Therapies to Optimize HIV Treatment

    Faculty: Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP


    Upon completion of this activity, participants will be better able to:

    • Apply updated HIV treatment guidelines and emerging antiretroviral strategies to optimize care in both primary and specialty settings.

    • Evaluate opportunities to advance health equity and its impact on treatment adherence and long-term viral suppression.

    • Integrate innovative treatment approaches, such as long-acting regimens and regimen simplification, into patient-centered care.

    • Assess investigational and pipeline therapies for their potential to shape the future of HIV treatment and support durable viral suppression.


    Module 2: Management of Common Comorbidities for People Living with HIV 

    Faculty: David Alain Wohl, MD


    Upon completion of this activity, participants will be better able to:

    • Identify common comorbidities and co-infections (CIs) among people with HIV and their impact on treatment decisions

    • Summarize recent updates to HIV treatment guidelines related to co-infections and opportunistic infections (OIs)

    • Identify strategies to manage common comorbidities and co-infections, including notable medication contraindications

    • Explain the importance of prevention and wellness discussions with PWH, that includes vaccinations, to reduce impact of CIs and OIs


    Module 3: Treatment Innovations in HIV: A Focus on Aging and Long-Term Survivors 

    Faculty: Brian R. Wood, MD


    Upon completion of this activity, participants will be better able to:

    • Describe emerging strategies for CVD management in older adults with HIV and long-term HIV survivors.

    • Understand strategies for managing metabolic syndrome and HIV-associated weight changes.

    • Evaluate new approaches to diagnosing and treating osteoporosis and frailty in persons aging with HIV.

    • Discuss emerging care models tailored for older adults with HIV and long-term HIV survivors.


    Module 4: Improving Health Equity in HIV Management 

    Faculty: Kathleen A. McManus, MD, FIDSA


    Upon completion of this activity, participants will be better able to:

    • Explain inequities in HIV and social determinants of health impacting people with HIV (PWH)

    • Understand intersectionality of social determinants of health that impact HIV treatment among key populations

    • Identify model practices for optimizing HIV management/treatment among patients with competing priorities (e.g. persons experiencing homelessness, substance use disorders, transgender persons, young adults)


    Module 5: Management of Treatment-Experienced Patients with HIV Drug Resistance 

    Faculty: Onyema E. Ogbuagu, MBBCh, FIDSA


    Upon completion of this activity, participants will be better able to:

    • Describe the principles and timing of HIV resistance testing pertaining to current guideline recommendations. 

    • Identify essential HIV resistance mutations and their clinical relevance.

    • Develop an evidence-based management plan for first-line regimen failure in treatment-experienced patients. 

    • Evaluate emerging clinical trial data on managing multi-drug resistant HIV.


    Module 6: Applying HIV Treatment Individualization in Patient Care Scenarios 

    Faculty: Asa E. Radix, MD, PhD, MPH, FIDSA


    Upon completion of this activity, participants will be better able to:

    • Address HIV management needs of older adults with HIV

    • Address unique considerations of HIV management for transgender women

    • Apply HIV treatment knowledge to determine optimal ART regimens for patients

Accreditation, Credit, and Support

All modules are accredited. Participants can earn up to 1.0 credits/contact hours (CME, AAPA, ANCC, CPE, ASWB M1-5 Only, ABIM MOC) per module.  


In support of improving patient care, HealthHIV, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

Please see individual modules for exact credit designation amounts.

MOC Statement

A blue and white sign Description automatically generated with low confidencePlease see individual modules for exact credit designation amounts.


Physician Associate Credit Designation Statement

Please see individual modules for exact credit designation amounts.



Nursing Continuing Professional Development

Please see individual modules for exact credit designation amounts. 


Continuing Pharmacy Education

Please see individual modules for exact credit designation amounts. 


Type of Activity: Knowledge


Please see below for UAN numbers assigned to each module.

Module

Pharmacy UAN#

Module 1: Innovations in Antiretroviral Therapies to Optimize HIV Treatment

Pending

Module 2: Management of Common Comorbidities for People Living with HIV

JA4008396-0000-25-031-H02-P

Module 3: Treatment Innovations in HIV: A Focus on Aging and Long-Term Survivors

JA4008396-0000-25-029-H02-P

Module 4: Improving Health Equity in HIV Management

JA4008396-0000-25-030-H02-P

Module 5: Management of Treatment-Experienced Patients with HIV Drug Resistance 

JA4008396-0000-25-028-H02-P

Module 6: Applying HIV Treatment Individualization in Patient Care Scenarios 

JA4008396-0000-25-032-H02-P


 

Social Worker Continuing Education

Please see individual modules for exact credit designation amounts. 


Interprofessional Continuing Education (IPCE) Statement



Please see individual modules for exact credit designation amounts.




Support Statement

This program has been supported by an independent educational grant from Theratechnologies, Inc.

This program has continued support from Gilead Inc.


Planning Committee and Content/Peer Reviewers The planners and content/peer reviewers from HealthHIV, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.
Faculty Disclosures

Please see individual modules for each faculty member’s disclosure.

All relevant financial relationships have been disclosed and mitigated in accordance with Joint Accreditation standards and HealthHIV Policy.



Disclosure & Conflict of Interest Policy

HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 80% or higher is needed to obtain credit.  Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.


For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.


For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC credit (80% is required for ABS).


For Pharmacists, HealthHIV  will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This Activity

HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV. 


The materials presented here are used with the permission of the authors and/or other sources. 


If you have any questions related to educational credits, including the type or amount of credit awarded, reporting of credits to certifying boards, or general accreditation-related inquiries, please contact the Accreditation Team at accreditation@healthhiv.org. A member of our team will be happy to assist you.


If you are experiencing issues accessing or downloading your certificate of completion, or if you have questions specifically about your individual certificate, please reach out directly to Beth at beth@healthhiv.org.


Module 1: Innovations in Antiretroviral Therapies to Optimize HIV Treatment 2025


**Module 1 of the HealthHIV HIV Treatment Innovation Certificate Program™ is being revised to reflect updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV released on 9/25/25. We anticipate Module 1 will re-launch on 10/21/25. You may complete all other modules for credit during this time, however, the Final Certificate will not be available until Module 1 is live and you can successfully complete it.**

Module 2: Management of Common Comorbidities for People Living with HIV 2025

Faculty: David A. Wohl, MD

Course Description

This module provides considerations for managing and preventing common comorbidities, co-infections and opportunistic infections among PWH.

Target Audience

This activity is intended for experienced HIV care providers (HIV and ID specialists), as well as primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, and other professionals involved in the care of PWH.


  • Media: Enduring Material
  • Credit Start Date: September 30, 2025
  • Credit Expiration date: September 30, 2026
  • Time to Complete: 60 minutes per module

Educational Objectives

After completing this activity, the participant will be better able to:

  • Identify common comorbidities and co-infections (CIs) among people with HIV and their impact on treatment decisions
  • Summarize recent updates to HIV treatment guidelines related to co-infections and opportunistic infections (OIs)
  • Identify strategies to manage common comorbidities and co-infections, including notable medication contraindications
  • Explain the importance of prevention and wellness discussions with PWH, that includes vaccinations, to reduce impact of CIs and OIs

Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, AAPA, ANCC, CPE, ASWB, ABIM MOC)

            Joint accreditation logo
                                                                                                                              

In support of improving patient care, HealthHIV, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
HealthHIV designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement

A blue and white sign Description automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).



Physician Associate Credit Designation Statement
HealthHIV has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until September 30, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour.


Continuing Pharmacy Education

HealthHIV designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 


Type of Activity: Knowledge


Please see below for UAN numbers assigned below: 

JA4008396-0000-25-031-H02-P

Social Worker Continuing Education

ACE: approved continuing educationAs a Jointly Accredited Organization, HealthHIV is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses are approved under this program. Regulatory boards have the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 general continuing education credit.


Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Support Statement

This program has been supported by an independent educational grant from Theratechnologies Inc.

This program has continued support from Gilead Inc.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from HealthHIV, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.


Faculty Disclosures

David Alain Wohl, MD

Professor of Medicine in the Division of Infectious Diseases 

University of North Carolina, School of Medicine Co-Principal Investigator

Global UNC Infectious Diseases Clinical Trial Unit Site Leader

HIV Prevention and Treatment Clinical Trials Unit 

Chapel Hill, NC



Disclosure: David Wohl, MD has a relevant financial relationship with the following eligible companies: Serve/served as an advisor/consultant/independent contractor to Gilead Sciences, Viiv, Merck, EMD Serono, Regeneron, and Theratechnologies. 


Receives Research Support from these ineligible companies (research funding by principal or named investigator): Gilead, Viiv and Merck.


All relevant financial relationships have been disclosed and mitigated in accordance with Joint Accreditation standards and HealthHIV internal policy.



Disclosure & Conflict of Interest Policy

HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.  

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 80% or higher is needed to obtain credit.  Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.


For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.


For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC credit (80% is required for ABS).


For Pharmacists, HealthHIV  will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.


About This Activity

HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV. 


The materials presented here are used with the permission of the authors and/or other sources. 


If you have any questions related to educational credits, including the type or amount of credit awarded, reporting of credits to certifying boards, or general accreditation-related inquiries, please contact the Accreditation Team at accreditation@healthhiv.org. A member of our team will be happy to assist you.


If you are experiencing issues accessing or downloading your certificate of completion, or if you have questions specifically about your individual certificate, please reach out directly to Beth at beth@healthhiv.org.




Module 3: Treatment Innovations in HIV: A Focus on Aging and Long-Term Survivors


Faculty: Brian R. Wood, MD
Target Audience

This activity is intended for experienced HIV care providers (HIV and ID specialists), as well as primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, and other professionals involved in the care of PWH.


  • Media: Enduring Material
  • Credit Start Date: September 30, 2025
  • Credit Expiration date: September 30, 2026
  • Time to Complete: 60 minutes per module

Educational Objectives

After completing this activity, the participant will be better able to:

  • Describe emerging strategies for CVD management in older adults with HIV and long-term HIV survivors.
  • Understand strategies for managing metabolic syndrome and HIV-associated weight changes.
  • Evaluate new approaches to diagnosing and treating osteoporosis and frailty in persons aging with HIV.
  • Discuss emerging care models tailored for older adults with HIV and long-term HIV survivors.
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, AAPA, ANCC, CPE, ASWB, ABIM MOC)

            Joint accreditation logo
                                                                                                                              

In support of improving patient care, HealthHIV, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
HealthHIV designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement

A blue and white sign Description automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).



Physician Associate Credit Designation Statement
HealthHIV has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until September 30, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour.


Continuing Pharmacy Education

HealthHIV designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 


Type of Activity: Knowledge


Please see below for UAN numbers assigned below: 

JA4008396-0000-25-029-H02-P

Social Worker Continuing Education

ACE: approved continuing educationAs a Jointly Accredited Organization, HealthHIV is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses are approved under this program. Regulatory boards have the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 general continuing education credit.


Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Support Statement

This program has been supported by an independent educational grant from Theratechnologies Inc.

This program has continued support from Gilead Inc.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from HealthHIV, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.


Faculty Disclosures

Brian R. Wood, MD

Professor, Department of Medicine

Division of Allergy & Infectious Diseases


Medical Director

MW AETC ECHO Telehealth Program

University of Washington School of Medicine 

Seattle, WA


Disclosure: Brian R. Wood, MD has no relevant financial relationship with ineligible companies.



Disclosure & Conflict of Interest Policy

HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.  

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 80% or higher is needed to obtain credit.  Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.


For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.


For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC credit (80% is required for ABS).


For Pharmacists, HealthHIV  will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.


About This Activity

HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV. 


The materials presented here are used with the permission of the authors and/or other sources. 


If you have any questions related to educational credits, including the type or amount of credit awarded, reporting of credits to certifying boards, or general accreditation-related inquiries, please contact the Accreditation Team at accreditation@healthhiv.org. A member of our team will be happy to assist you.


If you are experiencing issues accessing or downloading your certificate of completion, or if you have questions specifically about your individual certificate, please reach out directly to Beth at beth@healthhiv.org.

Module 4: Improving Health Equity in HIV Management 2025

Faculty: Kathleen A. McManus, MD, MSc

Target Audience

This activity is intended for experienced HIV care providers (HIV and ID specialists), as well as primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, and other professionals involved in the care of PWH.


  • Media: Enduring Material
  • Credit Start Date: September 30, 2025
  • Credit Expiration date: September 30, 2026
  • Time to Complete: 60 minutes per module

Educational Objectives

After completing this activity, the participant will be better able to:

  • Explain inequities in HIV and social determinants of health impacting people with HIV (PWH)
  • Understand intersectionality of social determinants of health that impact HIV treatment among key populations
  • Identify model practices for optimizing HIV management/treatment among patients with competing priorities (e.g. persons experiencing homelessness, substance use disorders, transgender persons, young adults)

Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, AAPA, ANCC, CPE, ASWB, ABIM MOC)

            Joint accreditation logo
                                                                                                                              

In support of improving patient care, HealthHIV, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
HealthHIV designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement

A blue and white sign Description automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).



Physician Associate Credit Designation Statement
HealthHIV has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until September 30, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour.


Continuing Pharmacy Education

HealthHIV designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 


Type of Activity: Knowledge


Please see below for UAN numbers assigned below: 

JA4008396-0000-25-030-H02-P

Social Worker Continuing Education

ACE: approved continuing educationAs a Jointly Accredited Organization, HealthHIV is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses are approved under this program. Regulatory boards have the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 general continuing education credit.


Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Support Statement

This program has been supported by an independent educational grant from Theratechnologies Inc.

This program has continued support from Gilead Inc.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from HealthHIV, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.


Faculty Disclosures

Kathleen A. McManus, MD, MSc

Associate Professor of Medicine, Division of Infectious Diseases and International Health

Medical Director, UVA Ryan White HIV Clinic

University of Virginia, School of Medicine

Charlottesville, VA


Disclosure: Kathleen A. McManus, MD, FIDSA has no relevant financial relationship with ineligible companies.


Disclosure & Conflict of Interest Policy

HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.  

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 80% or higher is needed to obtain credit.  Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.


For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.


For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC credit (80% is required for ABS).


For Pharmacists, HealthHIV  will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.


About This Activity

HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV. 


The materials presented here are used with the permission of the authors and/or other sources. 


If you have any questions related to educational credits, including the type or amount of credit awarded, reporting of credits to certifying boards, or general accreditation-related inquiries, please contact the Accreditation Team at accreditation@healthhiv.org. A member of our team will be happy to assist you.


If you are experiencing issues accessing or downloading your certificate of completion, or if you have questions specifically about your individual certificate, please reach out directly to Beth at beth@healthhiv.org.




Module 5: Management of Treatment-Experienced Patients with HIV Drug Resistance 2025

Faculty: 

Onyema E. Ogbuagu, MBBCh, FIDSA

Target Audience

This activity is intended for experienced HIV care providers (HIV and ID specialists), as well as primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, and other professionals involved in the care of PWH.


  • Media: Enduring Material
  • Credit Start Date: September 30, 2025
  • Credit Expiration date: September 30, 2026
  • Time to Complete: 60 minutes per module

Educational Objectives

After completing this activity, the participant will be better able to:

  • Describe the principles and timing of HIV resistance testing pertaining to current guideline recommendations.
  • Identify essential HIV resistance mutations and their clinical relevance.
  • Develop an evidence-based management plan for first-line regimen failure in treatment-experienced patients.
  • Evaluate emerging clinical trial data on managing multi-drug resistant HIV.
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, AAPA, ANCC, CPE, ASWB, ABIM MOC)

            Joint accreditation logo
                                                                                                                              

In support of improving patient care, HealthHIV, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
HealthHIV designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement

A blue and white sign Description automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).



Physician Associate Credit Designation Statement
HealthHIV has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until September 30, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour.


Continuing Pharmacy Education

HealthHIV designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 


Type of Activity: Knowledge


Please see below for UAN numbers assigned below: 

JA4008396-0000-25-028-H02-P


Social Worker Continuing Education

ACE: approved continuing educationAs a Jointly Accredited Organization, HealthHIV is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses are approved under this program. Regulatory boards have the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 general continuing education credit.


Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Support Statement

This program has been supported by an independent educational grant from Theratechnologies Inc.

This program has continued support from Gilead Inc.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from HealthHIV, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.


Faculty Disclosures

Onyema E. Ogbuagu, MBBCh, FIDSA

Associate Professor of Medicine and Pharmacology

Director, Yale Antivirals and Vaccines Research Program

Yale School of Medicine

New Haven, CT


Disclosure: Onyema E. Ogbuagu, MBBCh, FIDSA has a relevant financial relationship with the following eligible companies: Serve/served as an advisor/consultant/independent contractor to Gilead Sciences and Viiv. 


All relevant financial relationships have been disclosed and mitigated in accordance with Joint Accreditation standards and HealthHIV internal policy.


Disclosure & Conflict of Interest Policy

HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.  

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 80% or higher is needed to obtain credit.  Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.


For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.


For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC credit (80% is required for ABS).


For Pharmacists, HealthHIV  will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.


About This Activity

HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV. 


The materials presented here are used with the permission of the authors and/or other sources. 


If you have any questions related to educational credits, including the type or amount of credit awarded, reporting of credits to certifying boards, or general accreditation-related inquiries, please contact the Accreditation Team at accreditation@healthhiv.org. A member of our team will be happy to assist you.


If you are experiencing issues accessing or downloading your certificate of completion, or if you have questions specifically about your individual certificate, please reach out directly to Beth at beth@healthhiv.org.

Applying HIV Treatment Individualization in Patient Case Scenario 2025

Faculty: 

Asa E. Radix, MD, PhD, MPH, FIDSA

Target Audience

This activity is intended for experienced HIV care providers (HIV and ID specialists), as well as primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, and other professionals involved in the care of PWH.


  • Media: Enduring Material
  • Credit Start Date: September 30, 2025
  • Credit Expiration date: September 30, 2026
  • Time to Complete: 30 minutes

Educational Objectives

After completing this activity, the participant will be better able to:

  • Address HIV management needs of older adults with HIV
  • Address unique considerations of HIV management for transgender women
  • Apply HIV treatment knowledge to determine optimal ART regimens for patients

Accreditation, Credit, and Support
Participants can earn up to 0.50 credits/contact hours (CME, AAPA, ANCC, CPE, ABIM MOC)

            Joint accreditation logo
                                                                                                                              

In support of improving patient care, HealthHIV, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
HealthHIV designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement

A blue and white sign Description automatically generated with low confidence

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).



Physician Associate Credit Designation Statement
HealthHIV has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until September 30, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 0.50 contact hour.


Continuing Pharmacy Education

HealthHIV designates this continuing education activity for 0.50 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education. 


Type of Activity: Knowledge


Please see below for UAN numbers assigned below: 

JA4008396-0000-25-032-H02-P


Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.


Support Statement

This program has been supported by an independent educational grant from Theratechnologies Inc.

This program has continued support from Gilead Inc.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from HealthHIV, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.


Faculty Disclosures

Asa E. Radix, MD, PhD, MPH, FIDSA

Associate Professor of Clinical Epidemiology

Columbia University, Mailman School of Public Health

Infectious Disease/HIV Specialist, Callen-Lorde Community Health Center

New York, NY


Disclosure: Asa E. Radix, MD, PhD, MPH, FIDSA has no relevant financial relationships with an eligible company.


Disclosure & Conflict of Interest Policy

HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.  

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 80% or higher is needed to obtain credit.  Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.


For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.


For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC credit (80% is required for ABS).


For Pharmacists, HealthHIV  will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.


About This Activity

HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV. 


The materials presented here are used with the permission of the authors and/or other sources. 


If you have any questions related to educational credits, including the type or amount of credit awarded, reporting of credits to certifying boards, or general accreditation-related inquiries, please contact the Accreditation Team at accreditation@healthhiv.org. A member of our team will be happy to assist you.


If you are experiencing issues accessing or downloading your certificate of completion, or if you have questions specifically about your individual certificate, please reach out directly to Beth at beth@healthhiv.org.




HIV Tx Innovation Final Certificate 2025

Module 1 of the HealthHIV HIV Treatment Innovation Certificate Program™ is being revised to reflect updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV released on 9/25/25. We anticipate Module 1 will re-launch on 10/21/25. You may complete all other modules for credit during this time, however, the Final Certificate will not be available until Module 1 is live and you can successfully complete it.


After completion of all five modules, please select to receive your final certificate.